AlloVir, (id:8092 ALVR)
0.550 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 3:07:53 PM)
Exchange closed, opens in 18 hours 22 minutes
About AlloVir,
Market Capitalization 66.90M
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
| Headquarters (address) |
1100 Winter Street Waltham 02451 MA United States |
| Phone | 617 433 2605 |
| Website | https://www.allovir.com |
| Employees | 8 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ALVR |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.515 - 2.48 |
| Market Capitalization | 66.90M |
| P/E trailing | -0.301 |
| P/E forward | -1.81 |
| Price/Book | 0.440 |
| Beta | 0.741 |
| EPS | -0.880 |
| EPS United States (ID:6, base:3402) | 24.22 |